Lixte Biotechnology's Lead Compound Reported To Be Active Against ...
Also of potential relevance to the use of LB-100 in hematological diseases is a report by investigators at the Moffitt Cancer Center, Tampa, Florida, that inhibition of protein phosphatase 2A (PP2A) is the mechanism of action by which the Celgene drug ...
PR Newswire (press release) - Wed, 25 Feb 2015 06:03



Immunotherapy, Personalized Medicine to Highlight Winter Hematology Meeting
Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the ...
OncLive - Fri, 20 Feb 2015 06:34

Winter Hematology Meeting Highlighted by Talks on Immunotherapy ...
Targeted Oncology - Fri, 20 Feb 2015 12:12

Internationally Acclaimed Lymphoma Expert Larry Kwak Will Join City of Hope
DUARTE, Calif.--(BUSINESS WIRE)--Acclaimed translational research scientist and physician Larry W. Kwak, M.D., Ph.D., will join City of Hope in a key leadership role within the institution's new Hematologic Malignancies and Stem Cell Transplantation ...
Business Wire (press release) - Thu, 26 Feb 2015 08:18



Pazopanib/Paclitaxel Combination Demonstrates Activity in Relapsed/Refractory ...
The antiangiogenic agent pazopanib combined with paclitaxel showed significant antitumor activity in a phase II study of patients with relapsed/refractory urothelial cancer. In patients evaluable for treatment response, the overall response rate (ORR ...
OncLive - Sat, 28 Feb 2015 07:00

Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results ...
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978 ...
MarketWatch - Fri, 27 Feb 2015 04:00

Stock Update: Biogen Idec Inc (NASDAQ:BIIB) - Biogen Idec and Sobi Announce ...
Jutia Group - Fri, 27 Feb 2015 12:37

Infinity Pharmaceuticals Rating Lowered to Sell at TheStreet (INFI)
The Company's lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective ...
Dakota Financial News - Fri, 27 Feb 2015 17:30

In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined ...
In certain cancers, PD-L1 may play a role in inhibiting the ability of T cells (necessary to help the body fight disease) to function properly, which results in the proliferation of tumors in the human body. Anti-PD-L1 antibody therapies have been ...
MarketWatch - Fri, 27 Feb 2015 11:30

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies
... hematopoietic stem cells for the treatment of adrenoleukodystropy,77 beta-thalassemia,78, 79 Wiskott–Aldrich syndrome80 and metachromatic leukodystropy81 as well as CAR T cells for hematologic diseases.22, 56, 82 Similar to gamma retroviral vectors ...
Nature.com - Fri, 27 Feb 2015 03:30


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014